Movement Alert|EVEREST MED Falls 5.05% in Regular Trading, Softer Broker View Continues to Weigh on Sentiment

Market Focus11-03

On November 3, EVEREST MED fell 5.05% in regular trading, trading at HK$25.6, with turnover of HK$65.13 million.

The main catalyst cited in public market information is continued digestion of a weaker broker stance, after UBS downgraded the stock to neutral and set a target price of RMB27, pressuring near-term risk appetite and the pace of valuation recovery.

Earlier positive fundamentals had included strong sales of Nefecon, first-half revenue of RMB1.148 billion, and a narrowing attributable net loss to RMB5.944 million, while another broker had previously upgraded the company to buy. More recently, the market focus shifted to the rating downgrade, outweighing support from commercialization progress and pipeline updates, including products spanning kidney disease, anti-infectives, and autoimmune diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment